Psoriasis (Nail / Palmoplantar) Drug Pipeline 2026

Remission & chronicity

Spontaneous remission

Spontaneous PASI90 remission essentially zero without treatment; natural fluctuation occurs but complete clearance rare; <5% achieve sustained spontaneous remission over 5 years

Best-intervention remission

IL-17/IL-23 biologics achieve PASI100 (complete skin clearance) in 40-87% depending on agent and timeframe; complete clearance is now a realistic treatment goal, not a rarity

Gap size

Large — most patients never reach biologic therapy despite clear eligibility; on-drug clearance rates are exceptional but drug-free remission after cessation is short (12-32 weeks median for PASI loss)

Primary barrier

access/practice

Most moderate-severe psoriasis patients remain on topicals or older systemics (methotrexate, cyclosporine) for years before biologics are offered; prior authorisation barriers significant; psoriasis is associated with cardiovascular risk requiring systemic treatment beyond skin clearance

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

IL12B 14 IL17A 76 IL17RA 1 IL1RL2 3 IL23A 8 IL36RN 1 JAK1 233 PDE4D 204 TNF 287 TYK2 223

IL12B

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
TILDRAKIZUMAB	↓ inhibits	Mechanistic	DGIdb
ADENOVIRAL TRANSDUCED HIL-12-EXPRESSING AUTOLOGOUS DENDRITIC CELLS INXN-3001 PLUS ACTIVATOR LIGAND INXN-1001	? unclear	Mechanistic	DGIdb
MIRIKIZUMAB	↓ inhibits	Mechanistic	DGIdb
EGEN-001	? unclear	Mechanistic	DGIdb
VIRULIZIN	? unclear	Mechanistic	DGIdb
ISOPROTERENOL	? unclear	Mechanistic	DGIdb
INFLIXIMAB	? unclear	Mechanistic	DGIdb
BRIAKINUMAB	↓ inhibits	Mechanistic	DGIdb
EBDAROKIMAB	↓ inhibits	Mechanistic	DGIdb
HUMANIZED SMART ANTI-IL-12 ANTIBODY	? unclear	Mechanistic	DGIdb
GUSELKUMAB	↓ inhibits	Mechanistic	DGIdb
BRAZIKUMAB	↓ inhibits	Mechanistic	DGIdb
USTEKINUMAB	↓ inhibits	Mechanistic	DGIdb
RISANKIZUMAB	↓ inhibits	Mechanistic	DGIdb

IL17A

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
M-1095	↓ inhibits	Mechanistic		DGIdb
ANTI-IL17A MONOCLONAL ANTIBODY CJM112	? unclear	Mechanistic		DGIdb
VUNAKIZUMAB	↓ inhibits	Mechanistic		DGIdb
SIMVASTATIN	? unclear	Mechanistic		DGIdb
IZOKIBEP	↓ inhibits	Mechanistic		DGIdb
CJM-112	~ modulates	Mechanistic		DGIdb
IXEKIZUMAB	↓ inhibits	Mechanistic		DGIdb
COVA322	? unclear	Mechanistic		DGIdb
FLUTICASONE/SALMETEROL	? unclear	Mechanistic		DGIdb
BRODALUMAB	? unclear	Mechanistic		DGIdb
REMTOLUMAB	↓ inhibits	Mechanistic		DGIdb
ABBV-257	? unclear	Mechanistic		DGIdb
BIMEKIZUMAB	↓ inhibits	Mechanistic		DGIdb
VIDOFLUDIMUS	? unclear	Mechanistic		DGIdb
ERYTHROMYCIN	? unclear	Mechanistic		DGIdb
TIBULIZUMAB	↓ inhibits	Mechanistic		DGIdb
TETRACYCLINE	? unclear	Mechanistic		DGIdb
MANNITOL	? unclear	Mechanistic		DGIdb
GENTAMICIN	? unclear	Mechanistic		DGIdb
SECUKINUMAB	↓ inhibits	Mechanistic		DGIdb
SIROLIMUS	? unclear	Mechanistic		DGIdb
BUDESONIDE	? unclear	Mechanistic		DGIdb
OMALIZUMAB	? unclear	Mechanistic		DGIdb
EDODEKIN ALFA	? unclear	Mechanistic		DGIdb
AFASEVIKUMAB	↓ inhibits	Mechanistic		DGIdb
FORMOTEROL FUMARATE	? unclear	Mechanistic		DGIdb
AZATHIOPRINE	? unclear	Mechanistic		DGIdb
PERAKIZUMAB	↓ inhibits	Mechanistic		DGIdb
CHEMBL4872876	↓ inhibits	Mechanistic	110.0 nM (Kd)	ChEMBL
CHEMBL4858175	↓ inhibits	Mechanistic	12.3 nM (Kd)	ChEMBL
CHEMBL4854787	↓ inhibits	Mechanistic	89.0 nM (Kd)	ChEMBL
CHEMBL4878993	↓ inhibits	Mechanistic	12.9 nM (Kd)	ChEMBL
CHEMBL4869568	↓ inhibits	Mechanistic	6.2 nM (Kd)	ChEMBL
CHEMBL4876088	↓ inhibits	Mechanistic	10.1 nM (IC50)	ChEMBL
CHEMBL4860250	↓ inhibits	Mechanistic	14.3 nM (IC50)	ChEMBL
CHEMBL4866932	↓ inhibits	Mechanistic	10.1 nM (IC50)	ChEMBL
CHEMBL4874078	↓ inhibits	Mechanistic	7.0 nM (IC50)	ChEMBL
CHEMBL4845695	↓ inhibits	Mechanistic	2.8 nM (IC50)	ChEMBL
CHEMBL4855085	↓ inhibits	Mechanistic	4.6 nM (IC50)	ChEMBL
CHEMBL4860574	↓ inhibits	Mechanistic	2.0 nM (IC50)	ChEMBL

Showing top 40 of 76 agents ranked by evidence tier.

IL17RA

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
BRODALUMAB	↓ inhibits	Mechanistic		DGIdb

IL1RL2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
SPESOLIMAB	? unclear	Mechanistic	DGIdb
IMSIDOLIMAB	↓ inhibits	Mechanistic	DGIdb
MAB92	? unclear	Mechanistic	DGIdb

IL23A

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
TILDRAKIZUMAB	↓ inhibits	Mechanistic	DGIdb
MIRIKIZUMAB	↓ inhibits	Mechanistic	DGIdb
USTEKINUMAB	↓ inhibits	Mechanistic	DGIdb
RISANKIZUMAB	↓ inhibits	Mechanistic	DGIdb
GUSELKUMAB	↓ inhibits	Mechanistic	DGIdb
BRAZIKUMAB	↓ inhibits	Mechanistic	DGIdb
BRIAKINUMAB	↓ inhibits	Mechanistic	DGIdb
EBDAROKIMAB	↓ inhibits	Mechanistic	DGIdb

IL36RN

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
SPESOLIMAB	? unclear	Mechanistic		DGIdb

JAK1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
TRICETAMIDE	↓ inhibits	Mechanistic		DGIdb
NEZULCITINIB	↓ inhibits	Mechanistic		DGIdb
IVARMACITINIB	↓ inhibits	Mechanistic		DGIdb
OCLACITINIB	↓ inhibits	Mechanistic		DGIdb
MOMELOTINIB	↓ inhibits	Mechanistic	11.0 nM (IC50)	DGIdb
DECERNOTINIB	↓ inhibits	Mechanistic		DGIdb
GOLIDOCITINIB	↓ inhibits	Mechanistic		DGIdb
UPADACITINIB	↓ inhibits	Mechanistic		DGIdb
LEPZACITINIB	↓ inhibits	Mechanistic		DGIdb
BREPOCITINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 30 [PMID: 37057760]	↓ inhibits	Mechanistic		DGIdb
WXFL10203614	↓ inhibits	Mechanistic		DGIdb
LIRUCITINIB	↓ inhibits	Mechanistic		DGIdb
VEXICITINIB	↓ inhibits	Mechanistic		DGIdb
ILGINATINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 5E [PMID: 28580438]	↓ inhibits	Mechanistic		DGIdb
COMPOUND 25AP [PMID: 37796543]	↓ inhibits	Mechanistic		DGIdb
ZEMPROCITINIB	↓ inhibits	Mechanistic		DGIdb
PEMBROLIZUMAB	? unclear	Mechanistic		DGIdb
AZD1480	↓ inhibits	Mechanistic		DGIdb
CERDULATINIB	↓ inhibits	Mechanistic		DGIdb
LONDAMOCITINIB	↓ inhibits	Mechanistic		DGIdb
JAK INHIBITOR 20A	↓ inhibits	Mechanistic		DGIdb
FILGOTINIB	↓ inhibits	Mechanistic		DGIdb
GUSACITINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 8L [PMID: 36053746]	↓ inhibits	Mechanistic		DGIdb
COMPOUND 13AC [PMID: 33256400]	↓ inhibits	Mechanistic		DGIdb
FEDRATINIB	↓ inhibits	Mechanistic	100.0 nM (IC50)	DGIdb
FILGOTINIB MALEATE	↓ inhibits	Mechanistic		DGIdb
PF-956980	↓ inhibits	Mechanistic		DGIdb
SDC-1801	↓ inhibits	Mechanistic		DGIdb
ROPSACITINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 18E [PMID: 31670517]	↓ inhibits	Mechanistic		DGIdb
UPADACITINIB HEMIHYDRATE	↓ inhibits	Mechanistic		DGIdb
BLOVACITINIB	↓ inhibits	Mechanistic		DGIdb
DEURUXOLITINIB	↓ inhibits	Mechanistic		DGIdb
RUXOLITINIB PHOSPHATE	↓ inhibits	Mechanistic		DGIdb
SOLCITINIB	↓ inhibits	Mechanistic		DGIdb
CEE321	↓ inhibits	Mechanistic		DGIdb
NIK INHIBITOR 12F	↓ inhibits	Mechanistic		DGIdb

Showing top 40 of 233 agents ranked by evidence tier.

PDE4D

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
RESVERATROL	? unclear	Mechanistic		DGIdb
ROLIPRAM	↓ inhibits	Mechanistic	390.0 nM (IC50)	DGIdb
&ALPHA;-MANGOSTIN DERIVATIVE 4E	↓ inhibits	Mechanistic		DGIdb
6-HYDROXY-5,7-DIMETHOXYFLAVONE	↓ inhibits	Mechanistic		DGIdb
TETOMILAST	↓ inhibits	Mechanistic		DGIdb
FLAVOXATE HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
DIFAMILAST	↓ inhibits	Mechanistic		DGIdb
CILOMILAST	↓ inhibits	Mechanistic	63.0 nM (IC50)	DGIdb
DOVRAMILAST	↓ inhibits	Mechanistic		DGIdb
CRISABOROLE	↓ inhibits	Mechanistic		DGIdb
VINCRISTINE	? unclear	Mechanistic		DGIdb
RONOMILAST	? unclear	Mechanistic		DGIdb
THEOPHYLLINE	↓ inhibits	Mechanistic		DGIdb
CDP840	↓ inhibits	Mechanistic	2.1 nM (IC50)	DGIdb
LEO 29102	↓ inhibits	Mechanistic		DGIdb
LIRIMILAST	? unclear	Mechanistic		DGIdb
QUETIAPINE FUMARATE	? unclear	Mechanistic		DGIdb
HT-0712	↓ inhibits	Mechanistic		DGIdb
GSK-256066	↓ inhibits	Mechanistic		DGIdb
COMPOUND 29 [MOSLIN ET AL., 2017]	↓ inhibits	Mechanistic		DGIdb
THEOPHYLLINE SODIUM GLYCINATE	↓ inhibits	Mechanistic		DGIdb
DYPHYLLINE	↓ inhibits	Mechanistic		DGIdb
MORACIN M	↓ inhibits	Mechanistic		DGIdb
ARCTIGENIN	↓ inhibits	Mechanistic		DGIdb
TOFIMILAST	? unclear	Mechanistic		DGIdb
PDE4 INHIBITOR 16	↓ inhibits	Mechanistic		DGIdb
LOTAMILAST	↓ inhibits	Mechanistic		DGIdb
TRANIMILAST	↓ inhibits	Mechanistic		DGIdb
OGLEMILAST	? unclear	Mechanistic		DGIdb
CBS-3595	↓ inhibits	Mechanistic		DGIdb
ENSIFENTRINE	↓ inhibits	Mechanistic		DGIdb
TALAROTERPHENYL A	↓ inhibits	Mechanistic		DGIdb
PAPAVERINE	? unclear	Mechanistic		DGIdb
APREMILAST	↓ inhibits	Mechanistic		DGIdb
TILDRAKIZUMAB	? unclear	Mechanistic		DGIdb
RO20-1724	↓ inhibits	Mechanistic		DGIdb
MK-0359	↓ inhibits	Mechanistic		DGIdb
ROFLUMILAST	↓ inhibits	Mechanistic		DGIdb
OXTRIPHYLLINE	↓ inhibits	Mechanistic		DGIdb
AWD-12-281	? unclear	Mechanistic		DGIdb

Showing top 40 of 204 agents ranked by evidence tier.

TNF

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
DICLOFENAC SODIUM	? unclear	Mechanistic	DGIdb
RDP58	? unclear	Mechanistic	DGIdb
METHYLENE BLUE	? unclear	Mechanistic	DGIdb
ORTATAXEL	? unclear	Mechanistic	DGIdb
CERTOLIZUMAB PEGOL	↓ inhibits	Mechanistic	DGIdb
OZORALIZUMAB	↓ inhibits	Mechanistic	DGIdb
THALIDOMIDE	? unclear	Mechanistic	DGIdb
HUANG LIAN	? unclear	Mechanistic	DGIdb
GOLIMUMAB	↓ inhibits	Mechanistic	DGIdb
CYCLOSPORINE	? unclear	Mechanistic	DGIdb
DOCETAXEL ANHYDROUS	? unclear	Mechanistic	DGIdb
HALOFUGINONE	? unclear	Mechanistic	DGIdb
ETANERCEPT	↓ inhibits	Mechanistic	DGIdb
ISIS 104838	? unclear	Mechanistic	DGIdb
GEMCITABINE	? unclear	Mechanistic	DGIdb
INDOMETHACIN	? unclear	Mechanistic	DGIdb
INSULIN, REGULAR, HUMAN	? unclear	Mechanistic	DGIdb
DIDANOSINE	? unclear	Mechanistic	DGIdb
5,7-DIHYDROXY-4-METHYLCOUMARIN	? unclear	Mechanistic	DGIdb
SOBLIDOTIN	? unclear	Mechanistic	DGIdb
STAVUDINE	? unclear	Mechanistic	DGIdb
CISPLATIN	? unclear	Mechanistic	DGIdb
MEROPENEM ANHYDROUS	? unclear	Mechanistic	DGIdb
AMPHOTERICIN B LIPOSOMAL	? unclear	Mechanistic	DGIdb
MIDAZOLAM HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
RIFAMPIN	? unclear	Mechanistic	DGIdb
AVX-470	? unclear	Mechanistic	DGIdb
KETOROLAC TROMETHAMINE	? unclear	Mechanistic	DGIdb
PRAZOSIN HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
RISPERIDONE	? unclear	Mechanistic	DGIdb
BENZO[E]PYRENE	? unclear	Mechanistic	DGIdb
ETHAMBUTOL HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
REMTOLUMAB	↓ inhibits	Mechanistic	DGIdb
SPIRONOLACTONE	? unclear	Mechanistic	DGIdb
OMEPRAZOLE	? unclear	Mechanistic	DGIdb
CARBOPLATIN	? unclear	Mechanistic	DGIdb
MITOMYCIN C ANALOG KW-2149	? unclear	Mechanistic	DGIdb
NAFAMOSTAT	? unclear	Mechanistic	DGIdb
ABBV-3373	~ modulates	Mechanistic	DGIdb
BACILLUS CALMETTE-GUERIN ANTIGEN	? unclear	Mechanistic	DGIdb

Showing top 40 of 287 agents ranked by evidence tier.

TYK2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
JAK3 INHIBITOR 34	↓ inhibits	Mechanistic		DGIdb
SDC-1801	↓ inhibits	Mechanistic		DGIdb
TOFACITINIB	↓ inhibits	Mechanistic	250.0 nM (Kd)	DGIdb
GOLIDOCITINIB	↓ inhibits	Mechanistic		DGIdb
TYK2 INHIBITOR 18 [WO2023227946]	~ modulates	Mechanistic		DGIdb
GDC-0214	↓ inhibits	Mechanistic		DGIdb
TAMATINIB	? unclear	Mechanistic		DGIdb
JAK INHIBITOR 20A	↓ inhibits	Mechanistic		DGIdb
NVP-TAE684	? unclear	Mechanistic		DGIdb
PEFICITINIB	↓ inhibits	Mechanistic		DGIdb
TYD-68	? unclear	Mechanistic		DGIdb
BREPOCITINIB	↓ inhibits	Mechanistic		DGIdb
LORPUCITINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 25AP [PMID: 37796543]	↓ inhibits	Mechanistic		DGIdb
TOZASERTIB	? unclear	Mechanistic	510.0 nM (Kd)	DGIdb
FILGOTINIB MALEATE	↓ inhibits	Mechanistic		DGIdb
DEURUXOLITINIB PHOSPHATE	↓ inhibits	Mechanistic		DGIdb
MOMELOTINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 13 [PMID: 34333981]	↓ inhibits	Mechanistic		DGIdb
DEUCRAVACITINIB	~ modulates	Mechanistic		DGIdb
CADEFRECITINIB	↓ inhibits	Mechanistic		DGIdb
RUXOLITINIB	↓ inhibits	Mechanistic	19.0 nM (IC50)	DGIdb
JNJ-7706621	? unclear	Mechanistic	32.0 nM (Kd)	DGIdb
BMS-986202	↓ inhibits	Mechanistic		DGIdb
FILGOTINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 30 [PMID: 37057760]	↓ inhibits	Mechanistic		DGIdb
SJ988497	? unclear	Mechanistic		DGIdb
RECOMBINANT INTERLEUKIN-2	? unclear	Mechanistic		DGIdb
CERDULATINIB	↓ inhibits	Mechanistic		DGIdb
EDODEKIN ALFA	? unclear	Mechanistic		DGIdb
RG-1530	? unclear	Mechanistic		DGIdb
FEDRATINIB	↓ inhibits	Mechanistic	150.0 nM (IC50)	DGIdb
UPADACITINIB	↓ inhibits	Mechanistic		DGIdb
SAR-20347	↓ inhibits	Mechanistic		DGIdb
ZOTIRACICLIB	↓ inhibits	Mechanistic		DGIdb
G&OUML; 6976	? unclear	Mechanistic		DGIdb
COMPOUND 13AC [PMID: 33256400]	↓ inhibits	Mechanistic		DGIdb
TYK2 INHIBITOR 14L	↓ inhibits	Mechanistic		DGIdb
OCLACITINIB	↓ inhibits	Mechanistic		DGIdb
ILORASERTIB	? unclear	Mechanistic		DGIdb

Showing top 40 of 223 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Psoriasis (Nail / Palmoplantar): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) Recruiting

NCT07116967 Phase: 3 Started: 2025-09-22

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 Completed

NCT06588738 Phase: 3 Started: 2024-08-20

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes ...

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis Completed

NCT06586112 Phase: 3 Started: 2024-07-25

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis Recruiting

NCT06979453 Phase: 3 Started: 2025-12-03

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) Recruiting

NCT07850310 Phase: 1 Started: 2026-10-20

The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people. This trial will help researchers learn about the safety of MK-8644 and if participants tolerate it. Tolerate means participants will receive MK-8644 in t...

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares Completed

NCT06013969 Phase: 4 Started: 2023-10-22

This study is open to adults with a serious skin disease called generalized pustular psoriasis (GPP) who have repeated flares of GPP. The purpose of this study is to find out whether a medicine called spesolimab helps people with repeated flares of GPP. Participants are given a single dose of spesol...

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis Recruiting

NCT04772079 Phase: 3 Started: 2021-03-23

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<...

A Phase 2 Study of HB0017 in Psoriasis Patients Completed

NCT06592274 Phase: 2 Started: 2024-09-30

This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis Completed

NCT06088199 Phase: 3 Started: 2023-10-24

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis Recruiting

NCT07449702 Phase: 2 Started: 2026-02-23

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Topical Diacerein in Psoriasis Vulgaris Recruiting

NCT07352306 Phase: 4 Started: 2026-04-11

The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical ...

Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis Completed

NCT06477237 Phase: 3 Started: 2024-03-29

This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in the treatment of moderate to severe plaque psoriasis in adults.

Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers Completed

NCT07254325 Phase: 1 Started: 2025-12-15

This is a randomized, double-blinded, controlled Phase I study of new process CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of new process CMAB015 versus Cosentyx（Secukinumab ） in healthy male subjects after a single dose....

An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis Recruiting

NCT07879885 Phase: 2 Started: 2025-07-31

The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis

A Phase 3 Clinical Study of QL2106 Injection Active Not Recruiting

NCT07511647 Phase: 3 Started: 2026-05-27

It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis. A total of 318 subjects are planned to be included and randomized at a ra...

Agents Found By Disease-Level Search

Searched directly from “Psoriasis (Nail / Palmoplantar)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

51 agents shown (approved or with trial evidence) — 41 not found by the gene-target search above.

Risankizumab

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT04713592 NCT04451720 NCT03675308

Ustekinumab

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT04761627 NCT01008995 NCT01008995

MethotrexateNOT in gene-target list

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00932113 NCT03402087 NCT02634801

Guselkumab

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT05049798 NCT04914429 NCT03573323

Secukinumab

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT03384745 NCT03020199 NCT02721966

UVB phototherapyNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT00748020 NCT00748020 NCT00940862

Deucravacitinib

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT05744466 NCT05124080 NCT07256015

deucravacitinib (BMS-986165)NOT in gene-target list

Approved · 3 trials · source: ClinicalTrials.gov
NCT03402087 NCT02931838 NCT03624127

Ixekizumab

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT02634801 NCT03573323 NCT02584855

Adalimumab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT04808739 NCT00940862

Placebo for RisankizumabNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT04713592 NCT05969223

Apremilast

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05744466 NCT03624127

Bimekizumab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT07219420 NCT06425549

Fumaric Acid EstersNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02634801 NCT03331835

vunakizumab (SHR-1314)NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT06182384 NCT06182384

Zasocitinib

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07286058

Secukinumab InjectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05891964

122-0551NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01698333

Indirubin 200μg/gNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01735864

Indirubin 100 μg/gNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01735864

Indirubin 50 μg/gNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01735864

Indirubin 10 μg/gNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01735864

TQH3906 capsulesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06542614

700 mg IVNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00867100

350 mg SCNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00867100

140 mg SCNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00867100

IL-17iNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05049798

M1095 (Sonelokimab)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03384745

The novel electrolyzed water sprayNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05770271

Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05282771

Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05282771

Med-JetNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04410237

secukinumab (AIN457A)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT01169844

AM001 Cream, 7.5%NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03005964

nb-UVBNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03020199

Etanercept plus tacrolimusNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00134394

Levia Narrow Band UVBNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02107482

ABP 654NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04761627

NP000888NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02995473

VenapunctureNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04080661

CabozantinibNOT in gene-target list